AKL International

AKL International is a clinical-stage pharmaceutical company based in the United Kingdom, dedicated to developing innovative treatments for chronic inflammatory diseases. The company's primary focus is on osteoarthritis, a condition with significant unmet medical needs and limited treatment options beyond palliative care. Their lead therapeutic candidate, APPA, is an orally administered small molecule drug that combines two synthetic secondary metabolites, apocynin and paeonol, which work synergistically to modulate the NF-κB and Nrf2 inflammatory pathways. By targeting these intracellular signaling pathways, APPA aims to provide both pain relief and potential disease-modifying effects without the gastrointestinal or cardiovascular side effects common to traditional NSAIDs. AKL International has successfully advanced APPA through Phase 2a clinical trials and maintains strong research collaborations with institutions such as the University of Liverpool.